文献速递肝病

Volixibat治疗成人非酒精性脂肪性肝炎:随机II期研究24周中期分析

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
PubMed 文献 · J Hepatol · 2020-03-29

这项双盲II期剂量探索研究纳入197例无肝硬化的NASH成人,随机接受Volixibat 5、10或20 mg或安慰剂每日一次治疗48周。预设24周中期分析(n=80)显示Volixibat未达到脂肪含量或ALT下降终点,研究因缺乏疗效终止;血清C4升高和胆固醇下降提示靶点 engaged。

要点

  • Volixibat未达到24周中期疗效终点,研究因缺乏疗效终止。
  • 血清C4升高和总胆固醇/LDL-C下降提示ASBT抑制的靶点 engagement。
  • 腹泻是最常见TEAE及导致停药的最常见TEAE。

核心结论

  • Volixibat抑制ASBT虽显示靶点 engaged,但未在NASH成人中产生肝脏相关治疗获益。

研究设计与样本

  • 双盲、II期剂量探索研究,纳入197例≥5%脂肪变且无肝硬化的NASH成人,随机接受Volixibat 5、10或20 mg或安慰剂每日一次治疗48周。
  • 预设24周中期分析纳入80例,评估MRI-PDFF下降≥5%和血清ALT下降≥20%的终点。

主要发现

  • Volixibat未达到24周中期分析的任一终点。
  • 接受任何剂量Volixibat者,血清C4从基线至24周平均增加38.5 ng/ml(SD 53.18)。
  • 接受任何剂量Volixibat者,血清总胆固醇平均下降14.5 mg/dl(SD 28.32),LDL-C平均下降16.1 mg/dl(SD 25.31),变化呈剂量依赖性。
  • 组织学分析中,安慰剂组达到主要终点的比例(38.5%,n=5/13)高于Volixibat组(30.0%,n=9/30)。
  • TEAE主要为轻中度,无与Volixibat相关的严重TEAE;腹泻为最常见TEAE及导致停药的最常见TEAE。

关键数值与推荐

  • 24周中期终点:MRI-PDFF下降≥5%和血清ALT下降≥20%。
  • 主要终点:48周时NAFLD活动度评分下降≥2分且纤维化无恶化。
  • 血清C4平均增加38.5 ng/ml(SD 53.18),总胆固醇平均下降14.5 mg/dl(SD 28.32),LDL-C平均下降16.1 mg/dl(SD 25.31)。

临床怎么用

  • Volixibat不应用于NASH治疗,因研究因缺乏疗效终止。
  • 腹泻是需关注的主要不良反应,可导致停药。

局限性

  • 预设中期分析样本量较小(n=80),组织学分析例数有限。
  • 研究因缺乏疗效终止,未完成48周主要终点评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. We studied the safety, tolerability and efficacy of volixibat in patients with NASH. METHODS: In this double-blind, phase II dose-finding study, adults with ≥5% steatosis and NASH without cirrhosis (N = 197) were randomized to receive volixibat (5, 10 or 20 mg) or placebo once daily for 48 weeks. The endpoints of a predefined interim analysis (n = 80), at week 24, were: ≥5% reduction in MRI-proton density fat fraction and ≥20% reduction in serum alanine aminotransferase levels. The primary endpoint was a ≥2-point reduction in non-alcoholic fatty liver disease activity score without worsening fibrosis at week 48. RESULTS: Volixibat did not meet either interim endpoint; the study was terminated owing to lack of efficacy. In participants receiving any volixibat dose, mean serum 7-alpha-hydroxy-4-cholesten-3-one (C4; a biomarker of bile acid synthesis) increased from baseline to week 24 (+38.5 ng/ml [SD 53.18]), with concomitant decreases in serum total cholesterol (-14.5 mg/dl [SD 28.32]) and low-density lipoprotein cholesterol (-16.1 mg/dl [SD 25.31]). These changes were generally dose-dependent. On histological analysis, a greater proportion of participants receiving placebo (38.5%, n = 5/13) than volixibat (30.0%, n = 9/30) met the primary endpoint. Treatment-emergent adverse events (TEAEs) were mainly mild or moderate. No serious TEAEs were related to volixibat. Diarrhoea was the most common TEAE overall and the most common TEAE leading to discontinuation. CONCLUSIONS: Increased serum C4 and decreased serum cholesterol levels provide evidence of target engagement. However, inhibition of ASBT by volixibat did not elicit a liver-related therapeutic benefit in adults with NASH. LAY SUMMARY: A medicine called volixibat has previously been shown to reduce cholesterol levels in the blood. This study investigated whether volixibat could reduce the amount of fat in the liver and reduce liver injury in adults with an advanced form of non-alcoholic fatty liver disease. Volixibat did not reduce the amount of fat in the liver, nor did it have any other beneficial effect on liver injury. Participants in the study generally tolerated the side effects of volixibat and, as in previous studies, the main side effect was diarrhoea. These results show that volixibat is not an effective treatment for people with fatty liver disease. CLINICAL TRIAL IDENTIFIER: NCT02787304.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Newsome PN, Palmer M, Freilich B, et al. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. J Hepatol. 2020. PMID: 32234329. doi:10.1016/j.jhep.2020.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。